FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer

Cancer Biology and Therapy

Volumn 14, Issue 8, 2013, Pages 711-719

  Lim, Bora ^a   Scicchitano, Angelique ^a   Beachler, Cheryl ^a   Gusani, Niraj ^b   Sarwani, Nabeel ^b   Yang, Zhaohai ^b   Staveley O'Carroll, Kevin ^b   Ashkenazi, Avi ^c   Portera, Chia ^b   El Deiry, Wafik S ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^c GENENTECH INC   (United States)

Author keywords

Apo2L; BRAF; Cancer therapy; Clinical experience; Colon cancer; Dulanermin; Patient; TRAIL

Indexed keywords

ANTIBIOTIC AGENT; B RAF KINASE; BEVACIZUMAB; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; DULANERMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; THYMIDYLATE SYNTHASE;

ADULT; ANASTOMOSIS; ANEMIA; ARTICLE; BILIARY TRACT DRAINAGE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CASE REPORT; CHOLANGITIS; CHOLECYSTECTOMY; COLON ADENOCARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CYTOREDUCTIVE SURGERY; DUODENUM; ENTERIC FEEDING; EXCISION; FEEDING APPARATUS; FINE NEEDLE ASPIRATION BIOPSY; GALLBLADDER; GENE MUTATION; GENETIC SCREENING; HEMICOLECTOMY; HOSPITAL ADMISSION; HUMAN; HYPERTHERMIC THERAPY; LIVER; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG METASTASIS; MALE; MEDICAL HISTORY; MULTIPLE CYCLE TREATMENT; OMENTUM; OVERALL SURVIVAL; PANCREAS; PARTIAL HEPATECTOMY; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; WEIGHT REDUCTION;

APO2L; BRAF; CANCER THERAPY; CLINICAL EXPERIENCE; COLON CANCER; DULANERMIN; PATIENT; TRAIL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS B-RAF; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84881408026     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25310     Document Type: Article

References (23)

1. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931-7; PMID:19884549; http://dx.doi.org/10.1200/JCO.2009.22.4295
2. Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, et al. Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers. Cancer Res 2005; 65:6063-9; PMID:16024606; http://dx.doi.org/10.1158/0008-5472.CAN-05-0404
3. Laurent-Puig P, Cayre A, Manceau G, Buc E, Bachet JB, Lecomte T, et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 2009; 27:5924-30; PMID:19884556; http://dx.doi.org/10.1200/JCO.2008.21.6796
4. Halliwell B. A super way to kill cancer cells? Nat Med 2000; 6:1105-6; PMID:11017139; http://dx.doi. org/10.1038/80436
5. von Roretz C, Lian XJ, Macri AM, Punjani N, Clair E, Drouin O, et al. Apoptotic-induced cleavage shifts HuR from being a promoter of survival to an activator of caspase-mediated apoptosis. Cell Death Differ 2013; 20:154-68; PMID:22955946; http://dx.doi. org/10.1038/cdd.2012.111
6. Cheng EH, Wei MC, Weiler S, Flavell RA, Mak TW, Lindsten T, et al. BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX-and BAK-mediated mitochondrial apoptosis. Mol Cell 2001; 8:705-11; PMID:11583631; http://dx.doi. org/10.1016/S1097-2765(01)00320-3
7. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2:647-56; PMID:12209154; http://dx.doi. org/10.1038/nrc883
8. Wang S, El-Deiry WS. TRAIL and apoptosis induction by TNF family death receptors. Oncogene 2003; 22:8628-33; PMID:14634624; http://dx.doi. org/10.1038/sj.onc.1207232
9. Roy S, Nicholson DW. Cross-talk in cell death signaling. J Exp Med 2000; 192:21-6; PMID:11034597; http://dx.doi.org/10.1084/jem.192.8.F21
10. Kandasamy K, Srinivasula SM, Alnemri ES, Thompson CB, Korsmeyer SJ, Bryant JL, et al. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release. Cancer Res 2003; 63:1712-21; PMID:12670926
11. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90; PMID:8663110; http://dx.doi.org/10.1074/jbc.271.22.12687
12. Paz-Ares L, Bálint B, de Boer RH, van Meerbeeck JP, Wierzbicki R, De Souza P, et al. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced nonsmall-cell lung cancer. J Thorac Oncol 2013; 8:329-37; PMID:23370314
13. Kindler HL, Richards DA, Garbo LE, Garon EB, Stephenson JJ Jr., Rocha-Lima CM, et al. A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. Ann Oncol 2012; 23:2834-42; PMID:22700995; http://dx.doi.org/10.1093/annonc/mds142
14. Demetri GD, Le Cesne A, Chawla SP, Brodowicz T, Maki RG, Bach BA, et al. First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study. Eur J Cancer 2012; 48:547-63; PMID:22240283; http://dx.doi. org/10.1016/j.ejca.2011.12.008
15. Lenk H, Tanneberger S, Müller U, Ebert J, Shiga T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989; 24:391-2; PMID:2791193; http://dx.doi.org/10.1007/BF00257449
16. Smith TL, Lee JJ, Kantarjian HM, Legha SS, Raber MN. Design and results of phase I cancer clinical trials: three-year experience at M.D. Anderson Cancer Center. J Clin Oncol 1996; 14:287-95; PMID:8558210
17. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104:155-62; PMID:10411544; http://dx.doi. org/10.1172/JCI6926
18. Mitsiades N, Poulaki V, Mitsiades CS, Koutras DA, Chrousos GP. Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases. Trends Endocrinol Metab 2001; 12:384-90; PMID:11595539; http://dx.doi.org/10.1016/ S1043-2760(01)00441-6
19. Zhan C, Wei X, Qian J, Feng L, Zhu J, Lu W. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J Control Release 2012; 160:630-6; PMID:22410115; http://dx.doi.org/10.1016/j. jconrel.2012.02.022
20. Kelly MM, Hoel BD, Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol Ther 2002; 1:520-7; PMID:12496481; http://dx.doi.org/10.4161/cbt.1.5.169
21. Ashley DM, Riffkin CD, Lovric MM, Mikeska T, Dobrovic A, Maxwell JA, et al. In vitro sensitivity testing of minimally passaged and uncultured gliomas with TRAIL and/or chemotherapy drugs. Br J Cancer 2008; 99:294-304; PMID:18594532; http://dx.doi. org/10.1038/sj.bjc.6604459
22. Mitsiades N, Poulaki V, Mitsiades C, Tsokos M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res 2001; 61:2704-12; PMID:11289151
23. Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, et al. Control of TRAI Linduced apoptosis by a family of signaling and decoy receptors. Science 1997; 277:818-21; PMID:9242611; http://dx.doi.org/10.1126/ science.277.5327.818